The abstract is read at the publisher; the summary is JClub's.
Soxataltinib produced an IRC-assessed 84.8% ORR (95% CI 76.4–91.0) in treatment-naïve and previously treated advanced RET fusion-positive NSCLC at median 19.3-month follow-up.
- Why it matters: Durable control of both systemic and intracranial disease remains difficult in RET fusion-positive NSCLC despite selective RET inhibitors.
- What they did: In a multicenter, single-arm phase 2 trial, soxataltinib was given to 56 treatment-naïve and 49 previously treated patients, with systemic and intracranial responses assessed by an independent review committee.
- The result: Median PFS was not reached overall, and intracranial ORR was 100% (4/4) in treatment-naïve and 60.0% (3/5) in previously treated patients, with grade ≥3 TRAEs in 76.2% and discontinuation for adverse events in 1.9%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.